Risk Off: Take Profits in Biotech Stocks… Update -1

Re-iterate call from Tuesday….futures down 0.8%-Russell down 2%, gold up, Japan and Europe down..

http://kootenayhomes.com/our-agents/richard-daoust-realtor/?type=grid Bad Tape Yesterday (7/7) Calls For Raising Cash

NASDAQ at 4451 up 6.58% YTD

  • Major ETFs and Fidelity (FBIOX) take a ~3% hit
  • All major market sectors weak with healthcare down 1%
  • Unusual weakness in many Rayno Life Science stocks
  • Small caps weak with IWM down 1.69%, up 2% YTD
  • Many former high fliers continued weak: CLDX, ICPT, INCY, NLNK, SGMO, SRPT

The market failed in a run to new highs as it approached within 10% of February peaks. Some of our focus stocks bucked the trend like Pharmacyclics (PCYC) up 2.79 % bouncing off the 2014 support level near $90. The Company was granted priority review for the Imbruvica sNDA last month. Qiagen (QGEN) and Regeneron (REGN) were also stable. Large cap biopharmaceutical stocks were down as much as 2%. http://airbubbl.com/?gclid=Cj0KCQiAi57gBRDqARIsABhDSMrhUcF2t2DfAYUIA8WvXMCV1-jmCWfxTUqnWwajzzkUyk_ovrE8hSsaAhSdEALw_wcB Summer trading is likely to be choppy so going into the fourth quarter with 10-20% cash buy Lyrica cheap is a good idea. Moreover Q2 financial results will give us visibility for large cap stocks.

Some candidates for profit taking within the Rayno Life Science Portfolios with YTD performance: Exact Sciences (EXAS) up 42%, Illumina (ILMN) up 61%, Regeneron (REGN) up 13.2%,  Sequenom (SQNM) up 64% and Vertex (VRTX) up 30.3%.

 

No comments yet.

Leave a Reply